ArticleScientific reports2019

Glucose lowering by SGLT2-inhibitor empagliflozin accelerates atherosclerosis regression in hyperglycemic STZ-diabetic mice.

Jan Pennig et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.